Poster Presentations Session IV
Poster Presentations Session IV Tuesday, May 19, 2015
POSTERS SET-UP: 3:30 PM - 3:45 PM
POSTERS DISPLAY HOURS: 3:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION: 6:45 PM - 7:45 PM
POSTERS DISMANTLE: 7:45 PM


Poster display locations are shown below the poster codes
CANCER - Clinical Outcomes Studies
PCN1
A1
BONE SAFETY PROFILE OF DENOSUMAB THERAPY: A PHARMACOVIGILANCE CHARACTERIZATION ANALYSIS
Ali AK
Eli Lilly and Company, Indianapolis, IN, USA

PCN2
A2
META-ANALYSIS OF THE SAFETY OF SIPULEUCEL-T IMMUNOTHERAPY IN PROSTATE CANCER
Ma J1, Xuan S2, Tak C1, Brixner D3
1University of Utah, Salt Lake City, UT, USA, 2Yale University, New Haven, CT, USA, 3University of Utah, Pharmacotherapy Outcomes Research Center, Program in Personalized Health, Salt Lake City, UT, USA

PCN3
A3
TREATMENT FOR CHEMOTHERAPY-RELATED COGNITIVE DYSFUNCTION: REVIEW OF THE LITERATURE
Meyers OI
Truven Health Analytics, Cambridge, MA, USA

PCN4
A4
HYPOFRACTIONED RADIOTHERAPY IN THE TREATMENT OF EARLY BREAST CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS
Andrade TR1, Segreto H2, Segreto R2, Nazario A2, Fonseca M2
1AxiaBio, São Paulo, Brazil, 2Federal University of São Paulo, São Paulo, Brazil

PCN5
A5
RISK OF CARDIOTOXICITY AND ALL-CAUSE MORTALITY IN BREAST CANCER PATIENTS AFTER ADJUVANT CHEMOTHERAPY OR HORMONAL THERAPY
Wittayanukorn S1, Qian J2, Westrick SC2, Billor N3, Johnson B4, Hansen RA2
1Auburn University, Harrison School of Pharmacy, Auburn, AL, USA, 2Auburn University, Auburn, AL, USA, 3Auburn University, College of Sciences and Mathematics, Auburn, AL, USA, 4East Alabama Medical Center; Edward via College of Osteopathic Medicine, Opelika, AL, USA

PCN6
A6
RACIAL/ETHNICITY DISPARITIES IN THE ASSOCIATION BETWEEN DIABETES AND PANCREATIC CANCER IN THE ELDERLY MEDICARE POPULATION
Lu K1, Yuan J1, Li M1, Wu J2
1University of South Carolina, Columbia, SC, USA, 2University of South Carolina, Greenville, SC, USA

PCN7
A7
COMORBIDITY AND POSTOPERATIVE OUTCOMES AMONG LUNG CANCER PATIENTS IN THE UNITED STATES
Nadpara PA
Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA

PCN8
A8
INCREASED PREVALENCE OF LIPID DISORDERS IN CANCER PATIENTS ADMITTED TO U.S. HOSPITALS
Delgado A1, Villarreal SM1, Koeller JM1, Frei BL2, Frei CR1
1The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA, 2University of the Incarnate Word, San Antonio, TX, USA

PCN9
A9
PRE-EXISTING TYPE 2 DIABETES MELLITUS AND EMERGENCY COLORECTAL SURGERY AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER
Deb A, Madhavan SS, Bose S, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PCN10
A10
PATTERNS OF CARE IN THE WORKUP AND MANAGEMENT OF NON-METASTATIC AND METASTATIC COLORECTAL CANCER
Seal B1, Shermock KM2, Asche CV3, Kreilick C1, Tangirala M1, Cameron J1, Kish J4, Zagadailov EA4, Eaddy M4
1Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 2The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 3University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 4Xcenda, Palm Harbor, FL, USA

PCN11
A11
THE BURDEN OF AML WITHIN THE <65 YEAR-OLD US POPULATION MAY BE HIGHER THAN ACCEPTED US REGISTRY ESTIMATES
Turbeville S1, Francis KM2, Behm I2, Chiu GR2, Sanchez H2, Morgan J1, Yakovich A1, Ward R1, Hyare P1
1Sunesis Pharmaceuticals, South San Francisco, MA, USA, 2Trinity Partners, Waltham, MA, USA

PCN12
WITHDRAWN

PCN13
A12
UNDERSTANING QALY GAINS ACROSS DIFFERENT TYPES OF CANCERS AND CANCER-RELATED INTERVENTIONS
Thorat T1, Chambers J1, Neumann PJ2
1Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PCN14
A13
COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER
Lin PL1, Hao Y2, Xie J3, Li N1, Ohashi E1, Koo V1, Wu EQ1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Inc., New York, NY, USA

PCN15
WITHDRAWN

PCN16
A14
COMPARATIVE EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION AGAINST CERVICAL ABNORMALITIES BY DOSE LEVEL IN A COHORT OF PRIVATELY-INSURED U.S. GIRLS
Bensimon AG1, Hernan MA2, Gibson T3, Fung V3, Chernew M3, Landrum MB4, Newhouse JP4, Schuster M3, Hsu J5
1Harvard University, Cambridge, MA, USA, 2Harvard T. H. Chan School of Public Health, Boston, MA, USA, 3Harvard Medical School, Boston, MA, USA, 4Harvard University, Boston, MA, USA, 5Associate Professor of Medicine, Boston, MA, USA

PCN17
A15
PREDICTING PHASE III SURVIVAL OUTCOMES USING PHASE II TRIAL DATA IN NSCLC AND RCC
Macaulay R, Tan H
PAREXEL, London, UK

PCN18
A16
URSODEOXYCHOLIC AND CHENODEOXYCHOLIC ACID EXERT DISTINCT CYTOTOXIC EFFECTS ON COLON CANCER CELLS
Pavlovic N1, Stankov K2, Stanimirov B1, Stojancevic M1, Kojic V3, Bogdanovic G3, Mikov M1
1Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro, 2Clinical Center of Vojvodina, Novi Sad, Serbia and Montenegro, 3Oncology Institute of Vojvodina, Novi Sad, Serbia and Montenegro

PCN19
A17
COMPARING THE EFFICACY OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR PREVENTION OF SKELETAL-RELATED EVENTS (SRES): A CRITICAL APPRAISAL OF THREE PIVOTAL TRIALS
Strite S1, Stuart ME2, Beckman V3, Öhrling K3
1Delfini Group, LLC, Portland, OR, USA, 2Delfini Group, LLC/UW School of Medicine, Seattle, WA, USA, 3Amgen Inc., Thousand Oaks, CA, USA

PCN20
A18
IS METFORMIN EXPOSURE ASSOCIATED WITH IMPROVED SURVIVAL IN HEAD AND NECK CANCER PATIENTS? A LARGE POPULATION-BASED COHORT STUDY
Alcusky MJ1, Keith S1, Karagiannis TS2, Rabinowitz C1, Louis D1, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN21
A19
IDENTIFICATION AND CHARACTERIZATION OF LONG TERM SURVIVAL POPULATION IN NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES
Luaces P1, Sanchez L1, Viada C1, Rodriguez PC1, Alvarez M1, Fonte C2, Muchene L3, Shkedy S3, Lage A1
1Center of Molecular Immunology, Havana, Cuba, 2Havana University, La Habana, Cuba, 3Hasselt University, Hasselt, Belgium

PCN22
A20
PRALATREXATE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Yang Y1, Hsu YE2, Chiu H3, Chen Y1, Hsieh C4, Lin W5
1National Taiwan University, Taipei, Taiwan, 2Taipei Medical University, Taipei, Taiwan, 3Chinese Medical University, Taichung, Taiwan, 4Oriental Institute of Technology, New Taipei City, Taiwan, 5Chang Jung Christian University, Tainan, Taiwan

PCN23
A21
HETEROGENEITY OF TREATMENT EFFECT OF ANDROGEN DEPRIVATION THERAPY IN PATIENTS WITH INCIDENT METASTATIC PROSTATE CANCER
Aly A1, Hussain A2, Mullins CD3
1Pharmerit International, Bethesda, MD, USA, 2University of Maryland School of Medicine, Baltimore, MD, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN24
B1
NUCLEOSIDE ANALOGUES, STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION
Tsan Y1, Lin M2, Ho W2, Chen P3
1Taichung Veterans General Hospital, Taichung, Taiwan, 2Department of Public Health, China Medical University, Taichung, Taiwan, 3Department of Public Health, National Taiwan University College of Public Health, Taipei, Taiwan

PCN25
B2
INCIDENCE AND PREVALENCE OF BASAL CELL CARCINOMA IN A LARGE UNITED STATES COMMERCIALLY INSURED POPULATION
Goldenberg G1, Karagiannis TS2, Palmer JB2, Lotya J3, O'Neill CB3, Kisa RM2, Herrera V2
1Mount Sinai School of Medicine, New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Ireland Ltd, Elm Park, Ireland

PCN26
B3
EPIDEMIOLOGY AND TREATMENT OF RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN THE EU5
Nersesyan K1, Robinson D1, Wolfe G1, Pelletier C2, Forsythe A3, Pomerantz D1
1Kantar Health, Horsham, PA, USA, 2Eisai, Woodcliff Lake, NJ, USA, 3Eisai Inc., Woodcliff Lake, NJ, USA

PCN27
B4
BONE PAIN, SKELETAL RELATED EVENTS AND OPIOID USE IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES
Valderrama A1, Eapen S2, Hennessey KA3, Jones C4, Wen L1, Germino J5, Duh MS3
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Analysis Group (at the time of study), Boston, MA, USA, 3Analysis Group, Boston, MA, USA, 4Analysis Group, In, Boston, MA, USA, 5Bayer Healthcare, Whippany, NJ, USA

PCN28
B5
PRE-EXISTING TYPE 2 DIABETES MELLITUS AND 5-YEAR MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH COLORECTAL CANCER
Goyat R, Madhavan SS, Bose S, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PCN29
WITHDRAWN

PCN30
B6
SHORT- AND LONG-TERM SURVIVAL ASSOCIATED WITH LAPAROSCOPIC VERSUS OPEN COLECTOMY IN EARLY-STAGE COLON CANCER: FINDINGS FROM A RETROSPECTIVE COHORT STUDY
Goyal RK, Davis KL
RTI Health Solutions, Research Triangle Park, NC, USA

PCN31
B7
OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER TREATED WITH 1ST-LINE ENDOCRINE THERAPY VS. CHEMOTHERAPY
Vekeman F1, Hao Y2, Cheng WY3, Fortier J4, Robitaille M5, Duh MS3
1Groupe d'analyse, Montreal, QC, Canada, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Analysis Group, Boston, MA, USA, 4Groupe d'analyse, Ltée, Montreal, QC, Canada, 5Groupe d'analyse, ltée, Montreal, QC, Canada

PCN32
B8
ADJUSTING OVERALL SURVIVAL ESTIMATES FOR TREATMENT SWITCHING: A CASE STUDY IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Naidoo S1, Ivanescu C2, Skaltsa K3, Phung D4, Holmstrom S4, Latimer N5
1Astellas Pharma Europe, Ltd, Chertsey, UK, 2Quintiles, Hoofddorp, The Netherlands, 3Quintiles Consulting, Barcelona, Spain, 4Astellas Pharma Global Development, Leiden, The Netherlands, 5University of Sheffield, Sheffield, UK

PCN33
B9
CONDITIONAL SURVIVAL PROBABILITIES FOR PREVIOUSLY UNTREATED ADVANCED MELANOMA PATIENTS RECEIVING IPILIMUMAB: MODEL BASED ANALYSIS
Lee D1, Kotapati S2, Porter J1, Hertel N3, Zagorska A4, Hatswell AJ1
1BresMed, Sheffield, UK, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Bristol Myers Squibb, Uxbridge, UK, 4Bristol-Myers Squibb, Rueil Malmaison, France

CANCER - Cost Studies
PCN34
B10
EXAMINING THE BUDGET IMPACT OF ADOPTING NETUPITANT/PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A U.S. HEALTH PLAN
Knoth RL1, Abouzaid S1, Faria C2, Powers A1
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Formerly Eisai, Inc., Woodcliff Lake, NJ, USA

PCN35
B11
LUNG CANCER ECONOMIC BURDEN FROM A PRIVATE HEALTHCARE SYSTEM PERSPECTIVE IN BRAZIL
Ferreira CN1, Santana CF2, Paloni Ed3, Campi Fd3, Rufino CS1
1Pfizer Brasil, São Paulo, Brazil, 2Pfizer, São Paulo, Brazil, 3Orizon, Barueri, Brazil

PCN36
B12
THE UTILIZATION OF LAPAROSCOPIC VERSUS OPEN LIVER RESECTION FOR HEPATOCELLULAR CARCINOMA OR SECONDARY COLORECTAL METASTASES: A BUDGET IMPACT ANALYSIS
Ondrejicka DA, Goldstein LJ
Johnson and Johnson Medical Companies, Markham, ON, Canada

PCN37
B13
ECONOMIC IMPACT OF THE ADDITION OF AXITINIB AS A SECOND LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA IN THE ECUATORIAN PUBLIC HEATHCARE SECTOR
Rosado-Buzzo A1, Albuja M2, Garcia-Molliendo L3, Luna-Casas G3
1Links and Links, Mexico City, Mexico, 2Pfizer Ecuador, Quito, Mexico, 3Links and links, Mexico City, Mexico

PCN38
B14
BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A U.S. PAYER PERSPECTIVE
Bui CN1, O'Day K2, Flanders S1, Oestreicher N3, Francis P3, Posta L1, Popelar B2, Tang H1, Balk M3
1Astellas Scientific and Medical Affairs, Northbrook, IL, USA, 2Xcenda, Palm Harbor, FL, USA, 3Medivation Inc, San Francisco, CA, USA

PCN39
B15
MODELING ANNUAL PROJECTED REVENUE IMPACT OF THERAPY INTRODUCTION FOR PATIENTS WITH BRAF V600 METASTATIC MELANOMA FROM A HOSPITAL PERSPECTIVE
Cinfio FN1, Bly CA1, Perk S1, Smolen LJ2, Day MA1, Klein RW1
1Medical Decision Modeling, Indianpolis, IN, USA, 2Medical Decision Modeling Inc., Indianapolis, IN, USA

PCN40
B16
UNIVERSAL VERSUS TARGETED SCREENING OF COLON CANCERS FOR LYNCH SYNDROME: COST AND DIAGNOSTIC EFFECTIVENESS ANALYSES BASED ON CLINICAL EXPERIENCE
Erten MZ1, Fernandez LP2, Zenali M1, McKinnon W3, Koliba C2, Jones C1, Greenblatt M1
1University of Vermont - College of Medicine, Burlington, VT, USA, 2University of Vermont, Burlington, VT, USA, 3University of Vermont Cancer Center, Burlington, VT, USA

PCN41
B17
HOSPITAL CANCER BURDEN IN ARGENTINA: COSTS, MORTALITY AND READMISSIONS
Insua J
Hospital Universitario Austral, Pacheco, Argentina

PCN42
B18
TREATMENT PATTERNS AND COSTS ASSOCIATED WITH SUNITINIB AND PAZOPANIB TREATMENT FOR RENAL CELL CARCINOMA: A COMMERCIAL HEALTH CLAIMS ANALYSIS
Harnett J, MacLean E, Bhattacharyya H, Cisar L, Hoang CJ, Mardekian J
Pfizer, Inc., New York, NY, USA

PCN43
B19
A COST COMPARISON OF SPLIT-DOSE REDUCED-VOLUME ORAL SULFATE SOLUTION (OSS) AND POLYETHYLENE GLYCOL WITH ELECTROLYTES SOLUTION (PEG-ELS)
Cleveland M1, Yermakov S2, Davis M2, Campbell R2, Huynh L2, Farraye F3, Yenikomshian M2
1Braintree Laboratories, Braintree, MA, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Boston Medical Center, Boston University School of Medicine, Boston, MA, USA

PCN44
B20
THE COSTS OF CANCER-RELATED ABSENTEEISM: A SYSTEMATIC REVIEW OF THE LITERATURE
Yu JS1, Seal B2, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

PCN45
B21
COST COMPARISON OF FIRST LINE METASTATIC RENAL CELL CARCINOMA TREATMENTS USING A RETROSPECTIVE CLAIMS DATASET
Margolis J1, Princic N2, Doan J3, Lenhart G2, Motzer R4
1Truven Health Analytics, Bala Cynwyd, PA, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Bristol-Myers Squibb, Wallingford, CT, USA, 4Memorial Sloan-Kettering Cancer Center, Memorial Hospital, New York, NY, USA

PCN46
C1
CHOICE OF SEQUENTIAL BIOLOGICAL THERAPIES IN METASTATIC COLORECTAL CANCER (MCRC): A COST COMPARISON ANALYSIS FOR WILD-TYPE KRAS MCRC PATIENTS IN BRAZIL
Tsuchiya CT, Kim HS, La Scala CS
Roche Brazil, São Paulo, Brazil

PCN47
C2
HEALTHCARE RESOURCE UTILIZATION AND MEDICAL CARE COST ASSOCIATED WITH NEW BIO-SURGICAL HEMOSTASIS IN CHINA
Ma Y1, Gu X2, Wu J3, Yue N4, Lyu R4
1China Health Insurance Research Association, Beijing, China, 2Dalian Medical University, Dalian, China, 3Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China, 4Johnson & Johnson Medical Device, Beijing, China

PCN48
C3
SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Lachaine J1, Lachance S2, Lambert-Obry V1, Bibeau J1
1University of Montreal, Montreal, QC, Canada, 2Maisonneuve-Rosemont Hospital, Montreal, QC, Canada

PCN49
C4
ESTIMATION OF DIRECT HEALTHCARE COSTS OF GYNECOLOGIC CANCER IN THE U.S.: AN ANALYSIS OF 2007-2011 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Park C, Lawson KA
The University of Texas at Austin, Austin, TX, USA

PCN50
C5
HOSPITAL UTILIZATION IN PATIENTS WITH EBSTEIN'S ANOMALY
Craver CW1, Belk K2
1MedAssets, Inc., Huntersville, NC, USA, 2MedAssets, Mooresville, NC, USA

PCN51
C6
HEALTH CARE UTILIZATION AND COST ASSOCIATED WITH RADIOIODINE REFRACTORY (RAI-R) DIFFERENTIATED THYROID CANCER (DTC)
Abouzaid S1, Li X1, Rietschel P2
1Eisai, Inc., Woodcliff Lake, NJ, USA, 2Eisai, Inc, Woodcliff Lake, NJ, USA

PCN52
C7
COSTS OF TREATING SKELETAL-RELATED EVENTS AMONG PROSTATE CANCER PATIENTS WITH BONE METASTASES IN A COMMERCIAL INSURED POPULATION IN THE US
Zhong Y1, Yao J2, Donga P3, Bilir SP4, Valderrama A5
1Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA, USA, 2Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 3IMS Health, Plymouth Meeting, PA, USA, 4IMS Health, San Francisco, CA, USA, 5Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

PCN53
C8
SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF PANCREATIC CANCER
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PCN54
C9
SYSTEMATIC REVIEW OF EPIDEMIOLOGY AND BURDEN OF CUTANEOUS T-CELL LYMPHOMA
Aggarwal S, Topaloglu H
NOVEL Health Strategies, Chevy Chase, MD, USA

PCN55
C10
RATES, TIMING, AND COSTS OF SHORT-TERM DISABILITY (STD) AND LONG-TERM DISABILITY (LTD) IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED MELANOMA
Hallmeyer S1, Gilloteau I2, Limone B3, Johnson W3, Malangone-Monaco E3
1Oncology Specialists SC, Park Ridge, IL, USA, 2Bristol-Myers Squibb, Princeton, NJ, USA, 3Truven Health Analytics, New York, NY, USA

PCN56
C11
REVIEW OF DISEASE BURDEN OF LUNG CANCER IN CHINA'S BEIJING AND SHANGHAI
HU C1, Huang L2, Zhao D2, Xu L2
1Astrazeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China

PCN57
C12
ACCESS OF ORAL CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN FIRST LINE TREATMENT IN BRAZIL: IMPACT TO THE PATTERNS OF CARE AND COST OF ILLNESS
Piedade A1, Goes L2, Minowa E1, Castro AP1, Alves AF1
1Evidências - Kantar Health, Campinas, Brazil, 2Evidencias - Kantar Health, Campinas, Brazil

PCN58
C13
HEALTHCARE UTILIZATION AND COSTS ASSOCIATED WITH MULTIPLE SWITCHING OF TYROSINE KINASE INHIBITOR THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Kropf P1, Barnes G2, Tang B2, Pathak A2, Issa J3
1Fox Chase Cancer Center, Philadelphia, PA, USA, 2Teva Pharmaceutical, Frazer, PA, USA, 3Temple University School of Medicine, Philadelphia, PA, USA

PCN59
C14
DIRECT MEDICAL COSTS OF HER2 POSITIVE BREAST CANCER MANAGEMENT IN IRAN: A CLAIMS DATABASE AND DATA MINING ANALYSIS
Ansaripour A1, Zendehdel K2, Uyl - de Groot CA3, NaemiSanatdost A4, Redekop WK1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Tehran Medical Sciences and Medical education University, Tehran, Iran, 3Leiden University Medical Center, Leiden, The Netherlands, 4Independent researcher, Virginia Beach, SC, USA

PCN60
C15
A COST-EFFECTIVENESS ANALYSIS OF A BIOMARKER TEST COMPARED TO STANDARD OF CARE SURVEILLANCE IN PATIENTS WITH BARRETT'S ESOPHAGUS
Bock JA1, Pitcavage J1, Snyder S1, Critchley-Thorne R2
1Geisinger Health System, Danville, PA, USA, 2Cernostics Inc., Pittsburgh, PA, USA

PCN61
C16
ASSESSING THE ECONOMIC BURDEN OF U.S. MEDICARE PATIENTS DIAGNOSED WITH NON-HODGKIN'S LYMPHOMA
Xie L1, Keshishian A1, Du J1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Columbia University, New York, NY, USA

PCN62
D1
ASSESSING THE ECONOMIC BURDEN AND HEALTH CARE RESOURCE UTILIZATIONS OF U.S. MEDICARE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
Xie L1, Keshishian A1, Du J1, Baser O2
1STATinMED Research, Ann Arbor, MI, USA, 2STATinMED Research, Columbia University, New York, NY, USA

PCN63
D2
SYSTEMATIC LITERATURE REVIEW OF COST OF ADVERSE EVENTS IN CANCER TREATMENTS IN THE US
Gala S, Nanavaty M
Market Access Solutions LLC, Raritan, NJ, USA

PCN64
D3
PERCEPTIONS OF BIOSIMILAR MONOCLONAL ANTIBODIES AMONGST EU5 BUDGET HOLDERS
Gardiner RB
Access Partnership, London, UK

PCN65
D4
THE CLINICAL AND ECONOMIC BURDEN OF POST-THORACOTOMY PAIN SYNDROME (PTPS) AFTER LUNG RESECTION SURGERY: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA
Ghosh SK1, Roy S2, Akerman E3, DeVenezia R3, Yoo A3, Li G3, Fegelman E1
1Johnson & Johnson (Ethicon), Cincinnati, OH, USA, 2Ethicon, Somerville, NJ, USA, 3Johnson & Johnson, New Brunswick, NJ, USA

PCN66
D5
THE CLINICAL AND ECONOMIC BURDEN OF SIGNIFICANT BLEEDING DURING LUNG RESECTION SURGERY: A RETROSPECTIVE MATCHED COHORT ANALYSIS OF REAL-WORLD DATA
Ghosh SK1, Roy S2, Daskiran M3, Levine R3, Yoo A3, Li G3, Fegelman E1
1Johnson & Johnson (Ethicon), Cincinnati, OH, USA, 2Ethicon, Somerville, NJ, USA, 3Johnson & Johnson, New Brunswick, NJ, USA

PCN67
D6
EVALUATING THE COST OF TREATING BLADDER CANCER WITH AND WITHOUT METASTASES
Seal B1, Shermock KM2, Asche CV3, Chang J1, Kreilick C1, Yao J1, Cameron J1, Morland K4, Zagadailov EA4, Eaddy M4
1Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 2The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 3University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 4Xcenda, Palm Harbor, FL, USA

PCN68
D7
COST OF CARE FOR GASTRIC CANCER IN PATIENTS WITH AND WITHOUT METASTASES
Shermock KM1, Asche CV2, Seal B3, Kreilick C3, Chang J3, Zagadailov EA4, Kish J4, Eaddy M4, Xia F3
1The Johns Hopkins Medical Institutions, Baltimore, MD, USA, 2University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 3Bayer Healthcare Pharmaceuticals, Whippany, NJ, USA, 4Xcenda, Palm Harbor, FL, USA

PCN69
D8
COST OF TREATMENT OF RADIOPHARMACEUTICAL AND CHEMOTHERAPY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES IN HOSPITAL SETTING
Wen L1, Valderrama A1, Carlton R2, Eaddy M2, Seal B1
1Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA, 2Xcenda, Palm Harbor, FL, USA

PCN70
D9
COST – EFFICACY STUDY FOR IPILIMUMAB IN THE CHILEAN MARKET
Rovegno M1, Llanos C2, Galleguillos S2, Garrido Lecca S3
1Departamento de Medicina Intensiva, Facultad de Medicina, Universidad Católica de Chile., Santiago, Chile, 2IAS, Facultad de Economía y Negocios, Universidad de Chile, Santiago, Chile, 3Bristol-Myers Squibb, Lima, Peru

PCN71
D10
BEVACIZUMAB FOR FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER PATIENTS WITH HIGH RISK OF RELAPSE: A COST EFFECTIVE OPTION FOR CANADIAN PATIENTS
Ghatage P1, Wright EJ2, Martin Nunez I2, Yin L2, Ray J3
1University of Calgary, Calgary, AB, Canada, 2Hoffmann-La Roche, Mississauga, ON, Canada, 3F. Hoffmann-La Roche, Basel, Switzerland

PCN72
D11
INDIRECT COSTS AMONG METASTATIC BREAST CANCER PATIENTS RECEIVING ERIBULIN
Wan Y1, Copher R2, Corman S1, Abouzaid S2, Gao X1
1Pharmerit International, Bethesda, MD, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA

PCN73
D12
COST-EFFECTIVENESS ANALYSIS OF ARSENIC TRIOXIDE FOR THE TREATMENT OF IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA
Tallman M1, Lo-Coco F2, Barnes G3, Kruse M4, Wildner R4, Martin M5, Mueller U6, Tang B3, Pathak A3, Weinstein MC7
1Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York City, NY, USA, 2University Tor Vergata, Rome, Italy, 3Teva Pharmaceutical, Frazer, PA, USA, 4Optum, Waltham, MA, USA, 5MAPI, Uxbridge, UK, 6Teva Pharmaceutical, Ulm, Germany, 7Harvard T. H. Chan School of Public Health, Boston, MA, USA

PCN74
D13
COST-EFFECTIVENESS OF RADIUM-223 DICHLORIDE (RADIUM-223) IN ALSYMPCA: A COST-EFFECTIVENESS ANALYSIS OF RADIUM-223+BEST STANDARD OF CARE (BSOC) COMPARED WITH PLACEBO+BSOC IN TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER (CRPC) AND SYMPTOMATIC BONE METASTASES IN CANADA
Henricks P1, Cislo P2, Zhan L2, Beaudet A3, Grabbi E4, Lloyd A4, Fleshner N5, Chin W6
1Bayer Inc, Toronto, ON, Canada, 2Bayer HealthCare, Whippany, NJ, USA, 3IMS Health, Basel, Switzerland, 4IMS Health, London, UK, 5Princess Margaret Hospital, University Health Network, Toronto, ON, Canada, 6ILEX Consulting, Toronto, ON, Canada

PCN75
D14
COST-EFFECTIVENESS ANALYSIS OF FEMALE HUMAN PAPILLOMAVIRUS VACCINATION IN MAINLAND CHINA
Gai R
National Center of Child Health and Development, Tokyo, Japan

PCN76
WITHDRAWN

PCN77
D15
USE OF ABIRATERONE IN THE MANAGEMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A REAL-LIFE COST-EFFECTIVENESS STUDY
Rocha J, Vanhuyse M, Aprikian A, Cury F, Kassouf W, Dragomir A
McGill University Health Centre, Montreal, QC, Canada

PCN78
D16
COST EFFECTIVENESS ANALYSIS OF ERIBULIN MESYLATE AS A TREATMENT FOR METASTATIC BREAST CANCER IN SPAIN: MANAGEMENT IN THE LATER LINES OF THERAPY
Majethia U1, Tremblay G2, Kontoudis I3, DeRosendo J4
1Eisai Inc., Woodcliff Lake, NJ, USA, 2Eisai, Woodcliff Lake, NJ, USA, 3Eisai Europe Ltd.,, Hatfield,, UK, 4Eisai Farmacéutica, S.A., Madrid, Spain

PCN79
E1
IDELALISIB PLUS RITUXIMAB VERSUS PLACEBO PLUS RITUXIMAB FOR RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA: A COST-EFFECTIVENESS ANALYSIS
Yu JS1, Seal B2, Carlson JJ1
1University of Washington, Seattle, WA, USA, 2Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA

PCN80
E2
COST-EFFECTIVENESS OF EML4-ALK GENE TARGETED FIRST-LINE CERITINIB TREATMENT AMONG PATIENTS WITH ADVANCED ALK-POSITIVE NON–SMALL CELL LUNG CANCER
Upadhyay N, Atreja N
University of Houston, Houston, TX, USA

PCN81
E3
COST-EFFECTIVENESS OF SORAFENIB FOR TREATMENT OF RADIOACTIVE IODINE (RAI)-REFRACTORY LOCALLY ADVANCED/METASTATIC DIFFERENTIATED THYROID CANCER (DTC) IN TURKEY
Erdal E1, Sayman H2, Turkmen C3, Aral F3, Yildiz O4, Okutur K5, Parali E1, Deger C1, Tunalioglu A1, Sar C1, Asan S1, Sumer F1, Ozel O1
1Bayer Turk Kimya San. Ltd. Sti., Istanbul, Turkey, 2Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 3Istanbul University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, 4Medipol University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, 5Acibadem University Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey

PCN82
E4
ECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT
Burbano X1, Palacios E1, Cardona D2, Canseco López FD3, Palacios García SA1, Huicochea-Bartelt JL4, Valencia C4, Herran S4
1Guia Mark, Distrito Federal, Mexico, 2Línea de Investigación en Epidemiología y Economía de la Salud. Grupo Promoción y Prevención Farmacéutica. Facultad de Ciencias Farmacéuticas y Alimentarias. Universidad de Antioquia, Medellín, Antioquia, Colombia, 3Hospital Enrique Cabrera C. SSDF, Distrito Federal, Mexico, 4Boehringer Ingelheim, Distrito Federal, Mexico

PCN83
WITHDRAWN

PCN84
E5
COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VS LIPEGFILGRASTIM TO REDUCE THE INCIDENCE OF FEBRILE NEUTROPENIA IN PATIENTS WITH EARLY STAGE BREAST CANCER OR NON-HODGKIN LYMPHOMA
Fust K1, Li X2, Maschio M3, Villa G4, Parthan A5, Barron R6, Weinstein MC7, Somers L8, Hoefkens C9, Lyman GH10
1OptumInsight, Waltham, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Optum, Burlington, ON, Canada, 4Amgen (Europe) GmbH, Zug, Switzerland, 5OptumInsight, Cambridge, MA, USA, 6Amgen, Inc., Thousand Oaks, CA, USA, 7Harvard T. H. Chan School of Public Health, Boston, MA, USA, 8OncoLogX, Antwerp, Belgium, 9Amgen Belgium, Brussels, Belgium, 10Fred Hutchinson Cancer Research Center, Seattle, WA, USA

PCN85
E6
COST-EFFECTIVENESS OF TREATING ADVANCED PROGRESSIVE PANCREATIC NEUROENDOCRINE TUMOR PATIENTS WITH EVEROLIMUS VERSUS SUNITINIB IN SWEDEN
Perrin A1, Park J2, Jacob J3, Welin S4
1LA-SER Analytica, New York, NY, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Novartis Sverige AB, Täby, Sweden, 4Akademiska sjukhuset/Uppsala University Hospital, Uppsala, Sweden

PCN86
E7
COST-EFFECTIVENESS OF CETUXIMAB+FOLFIRI VERSUS BEVACIZUMAB+FOLFIRI AT THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL – THE FIRE 3 TRIAL ECONOMIC PERSPECTIVE
Junqueira M1, de Campos MC1, Cardoso AP1, von Hohnhorst P2, Fujii RK1
1Merck Serono, São Paulo, Brazil, 2Merck Serono, Frankfurt, Germany

PCN87
E8
COST-EFFECTIVENESS OF MULTIPLEXED PREDICTIVE BIOMARKER SCREENING IN NON-SMALL CELL LUNG CANCER
Romanus D1, Cardarella S2, Cutler D1, Landrum MB1, Lindeman N3, Gazelle GS4
1Harvard University, Boston, MA, USA, 2Dana-Farber Cancer Institute, Boston, MA, USA, 3Brigham and Women's Hospital, Boston, MA, USA, 4Massachusetts General Hospital, Boston, MA, USA

PCN88
E9
WITHDRAWN

PCN89
E10
COST-EFFECTIVENESS ANALYSIS OF ADO-TRASTUZUMAB EMTANSINE COMPARED TO LAPATINIB-CAPECITABINE COMBINATION IN HER2-POSITIVE METASTATIC BREAST CANCER
Gor D, Lee W, Kim K, Mohan A, Peng K, Sarangpur S, Shinde S, Touchette D
University of Illinois at Chicago, Chicago, IL, USA

PCN90
E11
COST-EFFECTIVENESS OF A BIOPSY-BASED 8-PROTEIN PROGNOSTIC ASSAY TO OPTIMIZE TREATMENT DECISIONS IN GLEASON 3+3 AND 3+4 PROSTATE CANCER
Roth JA1, Ramsey S1, Carlson JJ2
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 2University of Washington, Seattle, WA, USA

PCN91
WITHDRAWN

PCN92
E12
COST EFFECTIVENESS ANALYSIS OF PANITUMUMAB + FOLFOX AS 1ST LINE OF TREATMENT OF MCRC RAS-WT
Alva ME1, Vargas J2
1Amgen, Mexico City, Mexico, 2Econopharma, Mexico City, Mexico

PCN93
E13
COST-EFFECTIVENESS OF CETUXIMAB+FOLFIRI VERSUS FOLFIRI AT THE PUBLIC HEALTHCARE SYSTEM IN BRAZIL – THE CRYSTAL TRIAL RAS SUBGROUP ECONOMIC PERSPECTIVE
Junqueira M1, de Campos MC1, Cardoso AP1, von Hohnhorst P2, Fujii RK1
1Merck Serono, São Paulo, Brazil, 2Merck Serono, Frankfurt, Germany

PCN94
E14
ECONOMIC EVALUATION OF TRANSARTERIAL CHEMOEMBOLIZATION WITH LIPIODOL VERSUS DRUG ELUTING BEAD FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS
Fouad S1, Elsisi G1, Elmahdawy M2
1Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt, 2Hospital Pharmacy Administration Central Administration for Pharmaceutical Affairs, Ministry of Health, Egypt, Cairo, Egypt

PCN95
E15
COST-EFFICACY ANALYSIS OF IPILUMUMAB IN PERU
Garrido Lecca S1, Donato BM2, Juarez-Garcia A3
1Bristol-Myers Squibb, Lima, Peru, 2Bristol-Myers Squibb Company, Wallingford, CT, USA, 3Bristol-Myers Squibb Company, Mexico City, Mexico

PCN96
E16
LONG-TERM OUTCOMES OF HPV VACCINATION IN PREVENTION OF ANAL CANCER IN OLDER HIV-POSITIVE MEN WHO HAVE SEX WITH MEN
Deshmukh AA1, Chhatwal J1, Chiao EY2, Nyitray AG3, Das P1, Cantor SB1
1The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2Baylor College of Medicine, Houston, TX, USA, 3The University of Texas School of Public Health, Houston, TX, USA

PCN97
F1
CASE STUDIES OF COST-EFFECTIVENESS FOR CO-ADMINISTERED BRANDED ONCOLOGY PRODUCTS: PREDICTIONS FROM AN EARLY ECONOMIC MODEL
Smith NJ1, Cordina G1, Cheynel J2, Blissett D2, Beckerman R1
1CBPartners, New York, NY, USA, 2CBPartners, London, UK

PCN98
F2
COST-EFFECTIVENESS OF CO-ADMINISTERED BRANDED THERAPIES IN ONCOLOGY: PRICING INSIGHTS FROM AN EARLY ECONOMIC MODEL
Smith NJ1, Cordina G1, Cheynel J2, Blissett D2, Beckerman R1
1CBPartners, New York, NY, USA, 2CBPartners, London, UK

PCN99
WITHDRAWN

PCN100
F3
A NEW APPROACH FOR IDENTIFICATION OF DISEASE-RELATED MEDICAL BILLING CODES FOR CHRONIC LYMPHOCYTIC LEUKEMIA FOR USE IN COST ANALYSES IN ADMINISTRATIVE CLAIMS DATA
Kozma C1, Slaton T2, Paris A3, Ellis L4
1C-K Consulting, St. Helena Island, SC, USA, 2C-K Consulting, West Columbia, SC, USA, 3Vigilytics, Victor, NY, USA, 4Janssen Scientific Affairs, LLC, Horsham, PA, USA

PCN101
F4
HOSPITAL UTILIZATION IN PATIENTS WITH MANTLE CELL LYMPHOMA
Belk K1, Craver CW2
1MedAssets, Mooresville, NC, USA, 2MedAssets, Inc., Huntersville, NC, USA

PCN102
F5
ASSESSING THE BURDEN OF ILLNESS AND HOSPITAL UTILIZATION OF POLYCEMIA VERA
Belk K1, Craver C2
1MedAssets, Mooresville, NC, USA, 2MedAssets, Huntersville, NC, USA

PCN103
F6
TIME AND MOTION STUDY FOR RITUXIMAB SC VS IV IN COLOMBIAN PATIENTS WITH NON-HODGKIN LYMPHOMA
Saenz Ariza SA
Productos Roche, Bogota, Colombia

PCN104
F7
VALUING SURVIVAL GAINS IN MYELODYSPLASTIC SYNDROMES ATTRIBUTABLE TO NOVEL CANCER THERAPIES
MacEwan JP1, Yin W2, Khan ZM3, Kaura S3
1Precision Health Economics, Los Angeles, CA, USA, 2University of California Los Angeles, Los Angeles, CA, USA, 3Celgene Corporation, Summit, NJ, USA

CANCER - Patient-Reported Outcomes & Patient Preference Studies
PCN105
F8
ADHERENCE TO TAMOXIFEN AND ARMOATASE INHIBITORS AMONG WOMEN ENROLLED IN MEDICAID PROGRAM
Khanna R, Joshi N, Pace P, Banahan III B
University of Mississippi, University, MS, USA

PCN106
F9
THE EFFECTIVENESS OF CAREPAK® ADHERENCE PACKAGING IN INCREASING LENALIDOMIDE THERAPY DURATION
Rice G, Nolan R, Grigorian M
Diplomat Specialty Pharmacy, Flint, MI, USA

PCN107
F10
MEASURING RISK FACTORS FOR NON-ADHERENCE USING PATIENT-REPORTED OUTCOMES IN STUDIES EVALUATING ADHERENCE WITH ORAL ANTINEOPLASTIC AGENTS: A 10-YEAR REVIEW
Mokiou S1, Hanson KA2
1UBC: An Express Scripts Company, London, UK, 2UBC: An Express Scripts Company, Dorval, QC, Canada

PCN108
F11
MEASUREMENT OF HEALTH STATE UTILITIES FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA BY USING TIME TRADE-OFF AND VISUAL ANALOG SCALE METHOD
Kang HN, Choi I, Song H, Park S, Suh D
Chung-Ang University, Seoul, South Korea

PCN109
F12
UTILITIES FOR HEALTH STATES IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND FACTORS INFLUENDING UTILITY VALUES
Choi I, Park S, Song J, Jun JH, Suh D
Chung-Ang University, Seoul, South Korea

PCN110
F13
MAPPING UTILITY SCORES FROM EUROPEAN ORGANIZATION FOR TREATMENT OF CANCER CORE-30 QUESTIONNAIRE SCORES (EORTC QLQ-C30) IN RELAPSED MULTIPLE MYELOMA
Ashaye AO1, Zhang J1, Bender RH2, Altincatal A1, Panjabi S3
1Evidera, Lexington, MA, USA, 2Evidera, Bethesda, MD, USA, 3Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA

PCN111
F14
EVAUATION OF CORCORDANCE BETWEEN PATIENT REPORTED OUTCOMES (PROS) AND CLINICIAN REPORTED OUTCOMES (CROS) IN PATIENTS WITH METASTATIC BRAIN DISEASE
Taychakhoonavudh S1, Lal L2, Swint J3
1Chulalongkorn University, Bangkok, Thailand, 2Cardinal Health, Missouri City, TX, USA, 3University of Texas School of Public Health, Houston, TX, USA

PCN112
F15
USING FACT DATA TO PREDICT PREFERENCE-BASED UTILITY MEASURES FOR PEOPLE WITH MALIGNANT MELANOMA: A REVIEW OF THE EVIDENCE
Ara R1, Paisley S1, Robinson AA1, Azough A2, Mensah L3
1The University of Sheffield, Sheffield, UK, 2Amgen Ltd., Uxbridge, UK, 3Amgen Ltd, Uxbridge, UK

PCN113
F16
PATIENT ACCESS TO CANCER CARE EXCELLENCE (PACE) SOUTH KOREA SURVEY
Lee E1, Kim Y2, Ramers-Verhoeven C3, Lee S4, Lee S4, Bae M4, Rajan N5, Orlando M6, Kim J4
1College of Pharmacy, Sungkyunkwan University, Suwon, South Korea, 2College of Medicine, Korea University, Seoul, South Korea, 3Eli Lilly, Houten, The Netherlands, 4Eli Lilly, Seoul, South Korea, 5Eli Lilly, West Ryde, Australia, 6Eli Lilly, Buenos Aires, Argentina

PCN114
G1
QUALITATIVE METHODS FOR ASSESSING PATIENT, CAREGIVER, AND PHYSICIAN–REPORTED EXPERIENCES WITH ORAL MEDICATIONS FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC)
Hazel-Fernandez LA1, Uribe C1, Flanders S2, Suehs B1, Dye T3
1Comprehensive Health Insights, Louisville, KY, USA, 2Astellas Scientific and Medical Affairs, Northbrook, IL, USA, 3University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

PCN115
G2
PATIENT PREFERENCES FOR PALLIATIVE TREATMENT OF LOCALLY ADVANCED OR METASTATIC GASTRIC CANCER AND ADENOCARCINOMA OF THE GASTROOESOPHAGEAL JUNCTION: A CHOICE-BASED CONJOINT ANALYSIS STUDY FROM GERMANY
Hofheinz R1, Clouth J2, Borchardt-Wagner J2, Wagner U2, Weidling E2, Jen M3, Brueck P2
1University Hospital Mannheim, Mannheim, Germany, 2Lilly Deutschland GmbH, Bad Homburg, Germany, 3Eli Lilly and Company, Surrey,, UK

PCN116
G3
PARTICIPATION IN CERVICAL CANCER SCREENING AND KNOWLEDGE ON HUMAN PAPILLOMAVIRUS AMONG WOMEN IN VÁC, HUNGARY
Vajda R1, Miskolczi A2, Horváthné Kívés Z1, Pakai A2, Gyuró M1, Molics B1, Csákvári T2, Répásy B1, Danku N1, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PCN117
G4
INCLUSION OF PATIENT-REPORTED OUTCOME MEASURES IN REGISTERED CLINICAL TRIALS: EVIDENCE FROM CLINICALTRIALS.GOV (2007-2013)
Vodicka E1, Kim K1, Devine B1, Gnanasakthy A2, Scoggins J3, Patrick DL1
1University of Washington, Seattle, WA, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3IMPAQ International, LLC, Columbia, MD, USA

PCN118
G5
TASTE DYSFUNCTION AFTER HEAD AND NECK CANCER TREATMENT: A META-ANALYSIS
McLaughlin LA
Saint Louis University, St. Louis, MO, USA

PCN119
G6
THE EMERGING ROLE OF PATIENT-REPORTED OUTCOMES (PROS) IN FDA HEMATOLOGY AND ONCOLOGY PRODUCT LABELS
Tse J, Shingler SL, Nixon A
PRMA Consulting, Hampshire, UK

PCN120
G7
DEVELOPMENT AND CONTENT VALIDITY TESTING OF THE PATIENT-REPORTED OUTCOMES OF FATIGUE IN CANCER (PROOF-C) SYMPTOM SEVERITY ASSESSMENT (SSA)
Yaworsky A1, Ojo O1, Foley C1, Bonthapally V2, Ma E2, Norquist J3, Pompilus F1, Pearson J3, Park J4, Arbuckle R5
1Adelphi Values Boston, Boston, MA, USA, 2Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Merck & Co Whitehouse Station, Whitehouse Station, NJ, USA, 4Alcon Laboratories, Inc., Fort Worth, TX, USA, 5Adelphi Values Ltd., Bollington, UK

PCN121
G8
PATIENT-REPORTED OUTCOMES (PROS) IN BLADDER CANCER
Barsdorf AI1, Pease S2
1Pfizer, Inc, New York, NY, USA, 2Pfizer, New York, NY, USA

PCN122
G9
PATIENT-REPORTED OUTCOMES (PROS) IN OVARIAN CANCER CLINICAL TRIALS
Pease S, Barsdorf AI
Pfizer, New York, NY, USA

PCN123
G10
DOES THE GENERIC CANCER OUTCOME MEASURE EORTC QLQ-C30 WORK IN MYELOFIBROSIS?
Mukuria CW, Brazier J, Rafia R
University of Sheffield, Sheffield, UK

PCN124
G11
DERIVATION OF A PREFERENCE-BASED MEASURE FOR METASTATIC BREAST CANCER USING THE EORTC QLQ-30 AND QLQ-BR 23
Hudgens S1, Lloyd A2, Campbell P1, Harrington A1, Forsythe A3
1Clinical Outcomes Solutions, Tucson, AZ, USA, 2Bladon Associates Ltd, Oxford, UK, 3Eisai Inc., Woodcliff Lake, NJ, USA

PCN125
G12
IMPACT OF ENZALUTAMIDE OR ABIRATERONE ACETATE + PREDNISONE (AbP) ON QUALITY OF LIFE (QoL) IN THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) THAT HAS PROGRESSED ON OR AFTER DOXETAXEL: A COMPARATIVE EFFECTIVENESS STUDY
Cella D1, Ivanescu C2, Phung D3, Mansbach H4, Holmstrom S3, Naidoo S5
1Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 2Quintiles Advisory Services, Hoofddorp, The Netherlands, 3Astellas Pharma Global Development, Leiden, The Netherlands, 4Medivation, Inc, San Francisco, CA, USA, 5Astellas Pharma EMEA, Chertsey, UK

PCN126
G13
HEALTH-RELATED QUALITY OF LIFE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CRITICAL LITERATURE REVIEW
Nussbaum N1, Dorff T2, Abernethy A1, Dolan C3, Flanders S4, Oestreicher N5, George DJ1
1Duke University Hospital, Durham, NC, USA, 2Keck Medicine of USC, Los Angeles, CA, USA, 3CMD Consulting, Inc., Sandy, UT, USA, 4Astellas Scientific and Medical Affairs, Northbrook, IL, USA, 5Medivation Inc, San Francisco, CA, USA

PCN127
G14
EXPLORATORY PSYCHOMETRIC ANALYSIS OF THE EQ-5D IN A MYELOFIBROSIS POPULATION
Rafia R, Mukuria CW
University of Sheffield, Sheffield, UK

PCN128
G15
QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION
Hayran M, Yüce D, Hüseyin B, Esin E, Kilickap S, Erman M, Celik I
Hacettepe University Cancer Institute, Ankara, Turkey

PCN129
G16
ELICITATION OF HEALTH-RELATED QUALITY-OF-LIFE CONCEPTS ASSOCIATED WITH TRIPLE-NEGATIVE BREAST CANCER
Holmstrom S1, Hawken NA2, Dam S3, Aballea S4, Oestreicher N5, Evans C6, Novak A1, Dydo M7
1Astellas Pharma Global Development, Leiden, The Netherlands, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3Creativ-Ceutical, Copenhagen, Denmark, 4Creativ-Ceutical, Paris, France, 5Medivation Inc, San Francisco, CA, USA, 6Endpoint Outcomes, Boston, MA, USA, 7Astellas Pharma Global Development, Northbrook, IL, USA

PCN130
G17
INVARIANCE OF QUALITY OF LIFE QUESTIONNAIRE EORTC QLQC30 IN DIFFERENT CANCER INDICATIONS
Viada C1, Ballesteros J2, Fors M3, Luaces P1, Sanchez L1, Alvarez M1, Frias A1, Crombet T1
1Center of Molecular Immunology, Havana, Cuba, 2University of the Basque Country, Leioa, Cuba, 3National Center of Clinical Trials, Havana, Cuba

CANCER - Health Care Use & Policy Studies
PCN131
G18
PATIENTS' GROUPS AND ADVOCACY IN ONCOLOGY: AWARENESS, SUPPORT AND UNMET NEEDS
Holtz L1, Minowa E2, Julian G3
1Oncoguia, São Paulo, Brazil, 2Evidências - Kantar Health, Campinas, Brazil, 3Evidências - Kantar Health, São Paulo, Brazil

PCN132
G19
INFLUENCE OF PATIENT-REPORTED OUTCOMES ON MARKET ACCESS DECISIONS IN DECENTRALIZED MARKETS (BRAZIL, ITALY, SPAIN, AND THE UNITED STATES)
Hogue S1, Brogan AP1, DeMuro C1, Barrett A1, D'Alessio D2, Bal V2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCN133
WITHDRAWN

PCN134
G20
THE DISCONNECT BETWEEN FUNDING DECISIONS OF CANCER DRUGS AND COMPANION DIAGNOSTIC TESTS IN CANADA
Poinas A, Wyatt G
Wyatt Health Management, Oakville, ON, Canada

PCN135
G21
ARE BIOMARKERS A BIG MARKET ACCESS BONUS? US AND EU5 PAYER PERSPECTIVES AND PRESCRIBING PATTERNS FOR KEY TARGETED NON-SMALL-CELL LUNG CANCER AGENTS
Cox J1, Roberts D1, Gheorghe D1, Moore R2
1Decision Resources Group, London, UK, 2Decision Resources Group, Nashville, TN, USA

PCN136
H1
CHARACTERIZATION OF TEMOZOLOMIDE UTILIZATION IN GLIOBLASTOMA
Hill K1, Jiang S2, Patel D2, Worthington K1
1Celldex Therapeutics, Hampton, NJ, USA, 2Pharmerit International, Bethesda, MD, USA

PCN137
H2
METASTATIC MELANOMA PATIENT CHARACTERISTICS AS A DETERMENING FACTOR FOR BRAF GENE MUTATION TESTING AND TREATMENT IN CANADA – A RETROSPECTIVE COHORT STUDY
Djokic S1, Lapierre M2
1IMS Health, Ottawa, ON, Canada, 2IMS Health, Kirkland, QC, Canada

PCN138
H3
BURDEN OF SYSTEMIC LIGHT-CHAIN (AL) AMYLOIDOSIS: A SYSTEMATIC LITERATURE REVIEW
Mehta S1, Cooke C1, Gao X1, Labotka R2, Berg D2, Parameswaran H3, Lin HM2
1Pharmerit International, Bethesda, MD, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Medical College of Wisconsin, Milwaukee, WI, USA

PCN139
H4
THE IMPACT OF ENDOSCOPIC LINEAR STAPLING DEVICE STABILITY IN THORACIC SURGERY: A DELPHI PANEL APPROACH
Miller D1, Gonzalez Rivas D2, Meyer K3, Clark RS4, Kohno T5
1WellStar Medical Group, Austell, GA, USA, 2Coruña University Hospital, Coruna, Spain, 3Xcenda Corporation, Tampa, FL, USA, 4Xcenda, Palm Harbor, FL, USA, 5Toranomon Hospital, Tokyo, Japan

PCN140
H5
THE EXPECTED IMPACT OF ONCOLOGY BIOSIMILARS IN BRAZIL AND MEXICO: PAYERS AND ONCOLOGISTS CONSIDER THE COST-EFFECTIVENESS OF THESE CHEAPER ALTERNATIVES
Zevallos S1, Ribeiro A2, Cox J3
1Decision Resources Group, Burlington, MA, USA, 2Decision Resources Group, Exton, PA, USA, 3Decision Resources Group, London, UK

PCN141
H6
PROMOTING MARKET ACCESS THROUGH BREAKTHROUGH THERAPY DESIGNATION: CAN THIS ACCOLADE HELP CONVINCE PAYERS AND PRESCRIBERS?
Duval A, Cox J
Decision Resources Group, London, UK

PCN142
H7
OPIOID PRESCRIPTION TRENDS IN THE RURAL US: EVIDENCE FROM THE NATIONAL AMBULATORY MEDICAL CARE SURVEY (NAMCS) DATA 2006-2010
Qureshi Z1, Haider MR1, Probst J2, Horner R1, Bennett C3
1University of South Carolina, Columbia, SC, USA, 2University of South Carolina, COLUMBIA, SC, USA, 3University of South Carolina College of Pharmacy, Columbia, SC, USA

PCN143
H8
PCODR – THE POINTLESS CANADIAN ONCOLOGY DRUG REVIEW?
Macaulay R, Surtel A
PAREXEL, London, UK

PCN144
H9
PRIORITY ACCESS FOR THE BIGGEST – VARIABLE PROVINCIAL ACCESS TO ONCOLOGY DRUGS IN CANADA
Macaulay R, Surtel A
PAREXEL, London, UK

PCN145
H10
COMPARING THE VALUE OF A PCODR FULL APPROVAL VERSUS AN APPROVAL CONDITIONAL ON COST-EFFECTIVENESS BEING IMPROVED TO AN ADEQUATE LEVEL
Macaulay R, Surtel A
PAREXEL, London, UK

PCN146
H11
REIMBURSEMENT APPROVAL OF ONCOLOGY DRUGS IN CANADA SUPPORTED BY A DATA PACKAGE LACKING PHASE III TRIAL DATA
Macaulay R
PAREXEL, London, UK

PCN147
H12
THE IMPACT OF ACCESS TO CANCER CARE ON ADJUVANT ENDOCRINE THERAPY USE AMONG BREAST CANCER SURVIVORS IN APPALACHIA
Tan X1, Marshall V1, Camacho F2, Anderson RT2, Balkrishnan R1
1University of Michigan, Ann Arbor, MI, USA, 2University of Virginia, Charlottesville, VA, USA

PCN148
H13
GENDER-SPECIFIC DIFFERENCES IN RISK FOR COST-RELATED MEDICATION NONADHERENCE AMONG CANCER SURVIVORS
Lee MJ, Li Y, Khan MM
University of South Carolina, COLUMBIA, SC, USA

PCN149
H14
PATTERN OF ADJUNCTIVE DRUG UTILIZATION IN ONCOLOGY DEPARTMENT
Gogineni S
chalapathi Institute of pharmaceutical Sciences, Guntr, India

PCN150
H15
US BURDEN OF ILLNESS ASSOCIATED WITH ADJUVANT THERAPY FOR STAGE I-III MELANOMA
Houts AC1, Ward M2, Oglesby A3, Walker MS1, Saverno K1
1Vector Oncology, Memphis, TN, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3GlaxoSmithKline, RTP, NC, USA

PCN151
WITHDRAWN

PCN152
H16
HIGH COST ONCOLOGY PRODUCTS DEMAND ADDITIONAL ADMINISTRATIVE BURDEN ON CLINICIANS IN SELECT EMEA MARKETS
Gardiner RB
Access Partnership, London, UK

PCN153
H17
BASELINE CHARACTERISTICS OF PATIENTS PROVIDED CANCER CARE WITHIN A NOVEL COMMERCIAL HEALTH PLAN CANCER CARE QUALITY PROGRAM
Willey V1, Quimbo R1, Tunceli O1, Mack M1, Malin J2
1HealthCore Inc., Wilmington, DE, USA, 2Anthem, Woodland Hills, CA, USA

PCN154
H18
THE IMPACT OF EARLY MEDICARE ADMINISTRATIVE CONTRACTOR IMPLEMENTATION ON THE RECEIPT OF CHEMOTHERAPY AND BIOLOGIC AGENTS BY MEDICARE COLON CANCER BENEFICIARIES WITH METASTATIC DISEASE
Vandigo J
University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN155
H19
THE ACCESS AND THE DIFFUSION OF ONCOLOGY DRUGS IN ALGERIA
Aissaoui A1, Kaddar M2, Soualmi R3
1Paris dauphine University, Paris, France, 2WHO, Oran, Algeria, 3University of Algiers, algier, Algeria

PCN156
H20
FACTORS AFFECTING TIME REQUIRED FOR PCODR DECISION MAKING
Macaulay R, Surtel A
PAREXEL, London, UK

PCN157
H21
IMPACT OF FEDERAL REGULATION ON ACCESS TO ORAL CHEMOTHERAPY (OC) AND HORMONAL THERAPY (HT) IN THE BRAZILIAN PRIVATE HEALTH SYSTEM (PHS)
Piedade A, Castro AP, Alves AF, Nishikawa AM, Minowa E
Evidências - Kantar Health, Campinas, Brazil

PCN158
I1
DETERMINANTS FOR GUIDELINE APPROPRIATE CARE AMONG ELDERLY WOMEN WITH STAGE I-III BREAST CANCER IN A SEER-MEDICARE POPULATION
LeMasters TJ, Madhavan SS, Sambamoorthi U, Kelly K, Hazard H, Long D
West Virginia University, Morgantown, WV, USA

PCN159
I2
VARIATIONS IN PRIMARY TREATMENT AMONG ELDERLY WOMEN WITH EARLY STAGE BREAST CANCER: ASSOCIATIONS WITH FACTORS RELATED TO OLD AGE AND VULNERABLE SOCIO-DEMOGRAPHICS
LeMasters TJ, Madhavan SS, Sambamoorthi U, Kelly K, Hazard H, Long D
West Virginia University, Morgantown, WV, USA

PCN160
I3
PAYERS' VIEWS ON HETEROGENEITY OF TREATMENT EFFECT IN ONCOLOGY
Aly A1, Mullins CD2
1Pharmerit International, Bethesda, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PCN161
I4
ACCESS TO A MEDICAL HOME AND ITS IMPACT ON HEALTHCARE UTILIZATION AND MEDICAL EXPENDITURE AMONGST CANCER SURVIVORS
Shah AB1, Li C2
1University of Arkansas for Medical Sciences, LITTLE ROCK, AR, USA, 2University of Arkansas for Medical Sciences, Little Rock, AR, USA

PCN162
WITHDRAWN

PCN163
WITHDRAWN

PCN164
I5
THE IMPACT OF GENOMIC TESTING ON CHEMOTHERAPY USE AND MEDICAL SPENDING IN A COMMERCIALLY-INSURED POPULATION OF BREAST CANCER PATIENTS
Epstein AJ1, Wong Y2, Mitra N1, Vachani A1, Hin S1, Yang L1, Smith-McLallen A3, Armstrong K4, Groeneveld PW1
1University of Pennsylvania, Philadelphia, PA, USA, 2Temple University Health System, Philadelphia, PA, USA, 3Independence Blue Cross, Philadelphia, PA, USA, 4Massachusetts General Hospital, Boston, MA, USA

PCN165
I6
INNOVATIVE PRICING MECHANISMS FOR THERAPIES FOR ADVANCED CANCERS
Wight CG, Tolley K
GalbraithWight Ltd., Polegate, UK

PCN166
I7
THE EVOLVING GLOBAL ROLE OF NONTRADITIONAL PAYERS AND REINSURANCE IN THE REIMBURSEMENT OF HIGH COST THERAPIES
Paul A1, Spinner DS2, Kristopik J1, Doyle JJ3, Faulkner E1
1Quintiles Consulting, Durham, NC, USA, 2Quintiles, Durham, NC, USA, 3Quintiles, Hawthorne, NY, USA

PCN167
I8
PERCEPTION OF VALUE OF NEW CANCER DRUGS: A SURVEY OF ONCOLOGISTS IN THE UNITED STATES (US)
Narayanan S
Ipsos Healthcare, columbia, MD, USA

PCN168
I9
AMERICANS' CANCER INFORMATION (CI) SEEKING EXPERIENCES AND SELF-EFFICACY (SE) IN SEEKING CANCER INFORMATION (CI): A CHARACTERISTIC SNAPSHOT USING 2012-13 HEALTH INFORMATION NATIONAL TRENDS SURVEY (HINTS)
Bhandari NR, Hwang M
ST. JOHN'S UNIVERSITY, Jamaica, NY, USA

PCN169
I10
AN ANALYSIS OF ONCOLOGY DRUG FINANCING IN HONG KONG
Sun D, Duttagupta S
CBPartners, New York, NY, USA

PCN170
WITHDRAWN

PCN171
I11
COMPARISON OF EXPECTED HEALTH IMPACTS FOR MAJOR CANCERS:INTEGRATION OF INCIDENCE RATE AND LOSS OF QUALITY-ADJUSTED LIFE EXPECTANCY
Hung M1, Lai W2, Chen HH3, Su W4, Wang J5
1Department of Public Health, National Cheng Kung University College of Medicine, Tainan, Taiwan, 2Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 3Department of Radiation Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 4Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 5National Cheng Kung University College of Medicine, Tainan, Taiwan

PCN172
I12
QUALITY OF EVIDENCE SUPPORTING INCLUSION OF PHARMACOGENOMIC BIOMARKERS IN PRODUCT LABELS OF FDA APPROVED ONCOLOGY THERAPIES
Jha RK, Gupta J, Kapoor A, Mazumder D
Optum Global Solutions, Noida, India

PCN173
I13
CARBOHYDRATE INTAKE AND BREAST CANCER RISK IN AFRICAN AMERICAN AND EUROPEAN AMERICAN WOMEN IN THE WOMEN'S CIRCLE OF HEALTH STUDY
Johnson NM1, Bandera E2
1ICON PLC, Morristown, NJ, USA, 2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

PCN174
I14
IMMUNE CHECKPOINT INHIBITORS AS ADJUVANTS: FUTURE CHALLENGES FOR PRICING AND REIMBURSEMENT
Wieffer HM1, McKendrick J2, Petropoulos A1, Saltman D1
1PRMA Consulting, Fleet, UK, 2PRMA Consulting, Hampshire, UK

PCN175
J1
PREDICTORS OF A POSITIVE CANCER DRUG FUND DECISION
Jaksa A, Liden D, Ho Y
Context Matters, New York, NY, USA

PCN176
J2
BARBEC(EU)D ONCOLOGY MARKET ACCESS – HOW BBQ PULLED PORK IS SIMILAR TO EUROPEAN P&R NEGOTIATIONS
Swilling N, Altier J
Simon-Kucher and Partners, Cambridge, MA, USA

PCN177
J3
IMPACT OF TOLERABILITY PROFILES ON HTA DECISION MAKING IN ONCOLOGY
Kreeftmeijer J1, Ryan J2, Van Engen A3, Heemstra L3
1Quintiles Consulting, Hoofddorp, The Netherlands, 2AstraZeneca, Cambridge, UK, 3Quintiles Advisory Services, Hoofddorp, The Netherlands

PCN178
WITHDRAWN

PCN179
J4
HIERARCHY OF CLINICAL ENDPOINTS IN HTA DECISION MAKING IN ONCOLOGY
Kreeftmeijer J1, Ryan J2, Van Engen A3, Heemstra L3
1Quintiles Consulting, Hoofddorp, The Netherlands, 2AstraZeneca, Cambridge, UK, 3Quintiles Advisory Services, Hoofddorp, The Netherlands

PCN180
J5
IS THERE AN IMPACT OF THE ORPHAN DESIGNATION IN ONCOLOGY ON MARKET ACCESS IN EUROPE?
Boiziau SC
EMAUD, Claude Bernard Lyon 1 University, Villeurbanne cedex, France

PCN181
J6
OPTIMISING MARKET ACCESS OF CANCER DRUGS IN CANADA: A STUDY OF ECONOMIC REVIEWS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW (PCODR) EXPERT COMMITTEE
Qu KQ1, Jiang Y2, Gauthier A2
1Amaris, Toronto, ON, Canada, 2Amaris, London, UK

PCN182
J7
USE OF MOLECULAR TESTING PRIOR TO FIRST-LINE ERLOTINIB THERAPY AMONG MEDICARE PATIENTS WITH STAGE IV NON-SMALL CELL LUNG CANCER
Romanus D1, Cutler D1, Keating NL1, Lennes IT2, Lamont E1, Gazelle GS2, Landrum MB1
1Harvard University, Boston, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA

PCN183
J8
ONCOLOGY DRUGS RECEIVING BREAKTHROUGH THERAPY DESIGNATION: CLINICAL TRIAL CHARACTERISTICS, DRUG PRICING, AND APPROVAL PROCESS
Park Y1, Vegesna A2, Ray D3, Tsang Y4
1University of Maryland College of Pharmacy, Baltimore, MD, USA, 2Thomas Jefferson University, Philadelphia, PA, USA, 3Rutgers University, Piscataway, NJ, USA, 4University of Maryland Baltimore, Baltimore, MD, USA

PCN184
J9
TREATMENT PATTERNS AMONG ELDERLY METASTATIC COLORECTAL CANCER PATIENTS - A SEER-MEDICARE ANALYSIS
Parikh RC, Du XL, Morgan RO, Lairson DR
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON, HOUSTON, TX, USA

PCN185
WITHDRAWN

PCN186
J10
CURRENT TREATMENT PATTERNS AND SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINDINGS FROM A BRIEF SURVEY OF EUROPEAN PHYSICIANS
Davis KL1, Lin HM2, Zhang S3, Kaye JA4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 4RTI Health Solutions, Waltham, MA, USA

PCN187
J11
TREATMENT PATTERNS OF ENDOCRINE THERAPY AND CHEMOTHERAPY AMONG POST-MENOPAUSAL WOMEN WITH HR+/HER2- METASTATIC BREAST CANCER
Lin PL1, Hao Y2, Signorovitch JE1, Kelley C1, Macalalad AR1, Ohashi E1, Zhou Z1, Wu EQ1
1Analysis Group, Inc., Boston, MA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.